Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals (NQ: IONS )

36.17 +2.16 (+6.35%)
Streaming Delayed Price Updated: 1:36 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 Next >
Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
Via Benzinga
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
Via Benzinga
Ionis Pharmaceuticals's Earnings Outlook
Via Benzinga
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile'
Via Benzinga
Analyst Expectations for Ionis Pharmaceuticals's Future
Via Benzinga
The Latest Analyst Ratings for Ionis Pharmaceuticals
Via Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
4 Analysts Have This to Say About Ionis Pharmaceuticals
Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter: 
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs
Via Benzinga
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss
The guidance stayed intact despite a wide second-quarter flop. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
Via Benzinga
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday
Via Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
Via Benzinga
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
3 Biotech Stocks to Sell in October
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
Via Benzinga
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%
Via Benzinga
Analyst Ratings for Ionis Pharmaceuticals
Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Ionis Pharmaceuticals: Q2 Earnings Insights
  Ionis Pharmaceuticals (NASDAQ:IONS) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.